Future Lipidology

Cardiovascular disease prevention and markers of hyperlipoproteinemia
pp. 255-258(4)
Authors: Gaddi, Antonio V; Malvi, Cristina

Pioglitazone boosts conventional lipid-lowering therapy for familial combined hyperlipidemia
pp. 259-261(3)

Omega-3 fatty acid ethyl esters (Omacor^®) for the treatment of hypertriglyceridemia
pp. 263-270(8)
Authors: Bhatnagar, Deepak; Hussain, Fatima

Prevention of childhood obesity: the new search for the holy grail?
pp. 271-276(6)
Author: Reilly, John J

Torcetrapib and atherosclerosis: what happened and where do we go from here?
pp. 277-284(8)
Author: Toth, Peter P

Investigational drugs targeting HDL-C metabolism and reverse cholesterol transport
pp. 285-301(17)
Authors: Robinson, Jennifer G; Davidson, Michael H

Role of nuclear PLC and PI3K signaling in the development of cancer
pp. 303-311(9)
Authors: Faenza, Irene; Ramazzotti, Giulia; Bavelloni, Alberto; Bregoli, Lisa; Fiume, Roberta; Gaboardi, Gian Carlo; Manzoli, Lucia; Matteucci, Alessandro; Martelli, Alberto M; Cocco, Lucio

Nutritional and nutraceutical considerations for dyslipidemia
pp. 313-339(27)
Authors: Sirtori, Cesare R; Anderson, James W; Arnoldi, Anna

Lysophospholipids: two-faced mediators in atherosclerosis
pp. 341-356(16)
Authors: Bot, Martine; Nofer, Jerzy-Roch; van Berkel, Theo JC; Biessen, Erik AL

Niemann-Pick type C disease proteins: orphan transporters or membrane rheostats?
pp. 357-367(11)
Authors: Munkacsi, Andrew B; Porto, Anthony F; Sturley, Stephen L